177 related articles for article (PubMed ID: 8494731)
1. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.
Li CJ; Miyamoto Y; Kojima Y; Maeda H
Br J Cancer; 1993 May; 67(5):975-80. PubMed ID: 8494731
[TBL] [Abstract][Full Text] [Related]
2. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.
Maeda H
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):169-85. PubMed ID: 11259839
[TBL] [Abstract][Full Text] [Related]
3. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
[TBL] [Abstract][Full Text] [Related]
4. SMANCS.
Duncan R
Jpn J Cancer Res; 1995 Jun; 86(6):inside front cover. PubMed ID: 7622412
[No Abstract] [Full Text] [Related]
5. [SMANCS/lipiodol].
Maeda H
Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
[TBL] [Abstract][Full Text] [Related]
6. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
Nagamitsu A; Greish K; Maeda H
Jpn J Clin Oncol; 2009 Nov; 39(11):756-66. PubMed ID: 19596662
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation.
Oka K; Miyamoto Y; Matsumura Y; Tanaka S; Oda T; Suzuki F; Maeda H
Pharm Res; 1990 Aug; 7(8):852-5. PubMed ID: 2146602
[TBL] [Abstract][Full Text] [Related]
8. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics].
Matsumura Y; Oda T; Maeda H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):821-9. PubMed ID: 2952066
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H; Sawa T; Konno T
J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
[TBL] [Abstract][Full Text] [Related]
10. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS.
Takeshita J; Maeda H; Kanamaru R
Gan; 1982 Apr; 73(2):278-84. PubMed ID: 6214446
[TBL] [Abstract][Full Text] [Related]
11. [Recent advances in research on SMANCS].
Maeda H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
[TBL] [Abstract][Full Text] [Related]
12. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura Y; Maeda H
Cancer Res; 1986 Dec; 46(12 Pt 1):6387-92. PubMed ID: 2946403
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of SMANCS on rat mammary tumor induced by 7,12-dimethylbenz[a]anthracene.
Kimoto A; Konno T; Kawaguchi T; Miyauchi Y; Maeda H
Cancer Res; 1992 Feb; 52(4):1013-7. PubMed ID: 1531320
[TBL] [Abstract][Full Text] [Related]
14. Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour LW
Crit Rev Ther Drug Carrier Syst; 1992; 9(2):135-87. PubMed ID: 1386002
[TBL] [Abstract][Full Text] [Related]
15. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin.
Suzuki F; Pollard RB; Maeda H
Cancer Immunol Immunother; 1989; 30(2):97-104. PubMed ID: 2480846
[TBL] [Abstract][Full Text] [Related]
17. [Tumor growth inhibitory effects of SMANCS, a poly (styrene-maleic acid) conjugated derivative of neocarzinostatin, on various tissue culture cells].
Suzuki F; Okuno Y; Maeda Y; Maeda H
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3305-12. PubMed ID: 2961306
[TBL] [Abstract][Full Text] [Related]
18. Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
Oda T; Yamamoto H; Miki T; Maeda H
Jpn J Cancer Res; 1989 Apr; 80(4):394-9. PubMed ID: 2526108
[TBL] [Abstract][Full Text] [Related]
19. [Styrene maleic acid neocarzinostatin-transcatheter embolization for hepatocellular carcinoma--third report].
Hasegawa I; Hirashima N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):253-9. PubMed ID: 11865632
[TBL] [Abstract][Full Text] [Related]
20. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Munakata T; Maeda H
Anticancer Res; 1988; 8(1):97-103. PubMed ID: 2451896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
